靛玉红类CDK1抑制剂的同源模建、分子对接及3D-QSAR研究

doi:10.3866/PKU.WHXB201312192

Abstract

Abstract:

The abnormal expression of cyclin-dependent kinase 1 (CDK1) leads to stagnation of the G2 phase and a variety of tumors. Therefore, CDK1 has been reported recently as an ideal cell cycle target for cancer drug discovery. In this paper, we use the cell division control protein 2 homolog as a template to homologically model the protein of CDK1 that is subsequently docked with the inhibitors of indirubin analogues. Three molecular alignment methods were used, and the corresponding three- dimensional quantitative structure-activity relationship (3D-QSAR) models were built using the comparative molecular field analysis (CoMFA) protocol in Sybyl 7.1 and the 3D-QSAR protocol (abbreviated for DS) in Discovery Studio 3.0. It was found that the molecular alignment method combining molecular docking with public template is most suitable for building the 3D-QSARmodels, and shows the best calculated results (CoMFA: q²=0.681, r²=0.909, and r_pred.²=0.836; DS: q²= 0.579, r²=0.971, and r_pred.²=0.795, where q² denotes the cross-validated correlation coefficient and r² denotes the non- cross- validated correlation coefficient). This paper may provide significant theoretical foundation for designing novel CDK1 inhibitors by carrying out structural modifications of indirubin analogues.

Key words: Cyclin-dependent kinase 1, Indirubin, 3D-QSAR, CoMFA, Homology modeling

ZHANG Qing-Qing, YAO Qi-Zheng, ZHANG Sheng-Ping, BI Le-Ming, ZHOU Zhi-Guang, ZHANG Ji. Homology Modeling, Molecular Docking, and 3D-QSAR of Indirubin Analogues as CDK1 Inhibitors[J]. Acta Phys. -Chim. Sin. 2014, 30(2), 371-381. doi: 10.3866/PKU.WHXB201312192

References

(1) Lees, E. Curr. Opin. Cell Biol. 1995, 7 (6), 773. doi: 10.1016/0955-0674(95)80060-3
(2) Zhang, L.; Zhu, H.;Wang, Q.; Fang, H.; Xu,W.; Li, M. J. Mol. Model. 2011, 17 (2), 219. doi: 10.1007/s00894-010-0710-z
(3) Quereda, V.; Malumbres, M. J. Mol. Endocrinol. 2009, 42 (2),75.
(4) Santamaria, D.; Barriere, C.; Cerqueira, A.; Hunt, S.; Tardy, C.;Newton, K.; Caceres, J. F.; Dubus, P.; Malumbres, M.; Barbacid,M. Nature 2007, 448 (7155), 811. doi: 10.1038/nature06046
(5) Wang, Q.; Su, L.; Niu, N.; Zhang, L.; Xu,W.; Fang, H. Curr. Med. Chem. 2011, 18 (13), 2025. doi: 10.2174/092986711795590110
(6) Singh, S. K.; Dessalew, N.; Bharatam, P. V. Med. Chem. 2007, 3 (1), 75. doi: 10.2174/157340607779317517
(7) McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Lemcke, T.;Kunick, C.; Sausville, E. A.; Zaharevitz, D.W.; Gussio, R.J. Biomol. Struct. Dyn. 2005, 22 (5), 493. doi: 10.1080/07391102.2005.10531227
(8) Gussio, R.; Zaharevitz, D.W.; McGrath, C. F.; Pattabiraman,N.; Kellogg, G. E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.;Meijer, L.; Sausville, E. A. Anticancer Drug Des. 2000, 15 (1),53.
(9) Li,W. Y.; Zhang, L.; Li, F. L.;Wang, Z. H.; Yao, Q. Z. World Notes Antibiot. 2009, 30 (3), 113. [李文赟, 张磊, 李福龙,王朝晖, 姚其正. 国外医药抗生分册, 2009, 30 (3), 113.]
(10) Beauchard, A.; Ferandin, Y.; Frere, S.; Lozach, O.; Blairvacq,M.; Meijer, L.; Thiery, V.; Besson, T. Bioorganic & Medicinal Chemistry 2006, 14 (18), 6434. doi: 10.1016/j.bmc.2006.05.036
(11) Ferandin, Y.; Bettayeb, K.; Kritsanida, M.; Lozach, O.;Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Meijer,L. J. Med. Chem. 2006, 49 (15), 4638. doi: 10.1021/jm060314i
(12) Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.;Snyder, G. L.; Greengard, P.; Biernat, J.;Wu, Y. Z.; Mandelkow,E. M.; Eisenbrand, G.; Meijer, L. J. Biol. Chem. 2001, 276 (1),251.
(13) Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos,P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.;Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.;Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. Chem. Biol.2003, 10 (12), 1255. doi: 10.1016/j.chembiol.2003.11.010
(14) Hyperchem, Release 7.0 forWindows; Hypercube, Inc.:Gainesville, 2002.
(15) Robbins, T. J.;Wang, Y.; Yao, Q. Z.;Wang, Z. H.; Cheng, J.; Li,Y. S. J. Mol. Struct. 2013, 1048, 51. doi: 10.1016/j.molstruc.2013.05.012
(16) Tian, F. A.; Li, C. M.; Gong, K. C.; Zhou, Z. H.; Mao, Z. H.;Guo, Y. H. Chin. J. Med. Chem. 1994, 4 (12), 101. [田发安, 李春敏, 龚考才, 周宗华, 毛治华, 郭韵洪. 中国药物化学杂志,1994, 4 (12), 101.]
(17) Discovery Studio 3.0; Accelrys Inc.: San Diego, CA.
(18) Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida,T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.;Morishima, H. J. Med. Chem. 2001, 44 (26), 4615. doi: 10.1021/jm0103256
(19) Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.;Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.J. Biol. Chem. 2001, 276 (29), 27548. doi: 10.1074/jbc.M102060200
(20) Zhang, N.; Jiang, Y. J.; Zou, J.W.; Zeng, M.; Hu, G. X.; Yu, Q.S. Acta. Chim. Sin. 2005, 63 (9), 809. [张娜, 蒋勇军, 邹建卫, 曾敏, 胡桂香, 俞庆森. 化学学报, 2005, 63 (9), 809.]
(21) Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand,G.; Endicott, J. A.; Noble, M. E. M. Structure 2001, 9 (5),389. doi: 10.1016/S0969-2126(01)00598-6
(22) Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.;Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.;Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L.J. Med. Chem. 2004, 47 (4), 935. doi: 10.1021/jm031016d
(23) SYBYL 7.1; Tripos Inc.: St. Louis, Missouri, 63144, U.S.A.

[1]	Yu-Ling DENG,Lu YU,Qiang HUANG. A Multi-Target Docking System of Human Kinome [J]. Acta Phys. -Chim. Sin., 2016, 32(9): 2355-2363.
[2]	Feng LIN,Xin-Mei FU,Chao WANG,Si-Yu JIANG,Jing-Hui WANG,Shu-Wei ZHANG,Ling YANG,Yan LI. QSAR, Molecular Docking and Molecular Dynamics of 3C-like Protease Inhibitors [J]. Acta Phys. -Chim. Sin., 2016, 32(11): 2693-2708.
[3]	Shu-Zhen. ZHANG,Chao. ZHENG,Chang-Jin. ZHU. Molecular Docking and Receptor-Based 3D-QSAR Studies on Aromatic Thiazine Derivatives as Selective Aldose Reductase Inhibitors [J]. Acta Phys. -Chim. Sin., 2015, 31(12): 2395-2404.
[4]	LIN Ke-Jiang, ZHU Dong-Ji, LENG Yong-Gan, YOU Qi-Dong. Structural Characterization of Human Parathyroid Hormone 1 Receptor [J]. Acta Phys. -Chim. Sin., 2012, 28(07): 1783-1789.
[5]	QIAO Kang, ZENG Ling-Xiao, JIN Hong-Wei, LIU Zhen-Ming, ZHANG Liang-Ren. QSAR Analysis of Human Adenosine A₃ Receptor Antagonists [J]. Acta Phys. -Chim. Sin., 2012, 28(06): 1509-1519.
[6]	JIN Yi, WANG Yue, BIAN Fu-Yong, SHI Qiang, GE Mao-Fa, WANG Shu, ZHANG Xing-Kang, XU Si-Chuan. Three-Dimensional Structure of Dopamine 3-Subtype Receptor with the Active Site Residues for the Binding of Dopamine [J]. Acta Phys. -Chim. Sin., 2011, 27(10): 2432-2446.
[7]	KE Yan-Rong, JIN Hong-Wei, LIU Zhen-Ming, ZHANG Liang-Ren. Homology Modeling and Structure Validation of the Adenosine A₁ Receptor [J]. Acta Phys. -Chim. Sin., 2010, 26(10): 2833-2839.
[8]	ZHANG Yuan, CHEN Ya-Dong, YOU Qi-Dong, ZOU Li-Yun, YANG Yan. Homology Modeling and Molecular Docking Studies on the Selectivity of HDAC1/HDAC8 [J]. Acta Phys. -Chim. Sin., 2010, 26(06): 1676-1686.
[9]	DUAN Hong-Xia, WANG Rui-Gang, ZHANG Jian-Jun, DONG Yan-Hong, LIANG Xiao-Mei, WU Jing-Ping, WANG Dao-Quan. QSAR of Macrolactone Derivatives with Herbicidal Activity [J]. Acta Phys. -Chim. Sin., 2010, 26(04): 1065-1074.
[10]	LV Wen, LV Wei, NIU Yan, LEI Xiao-Ping. HomologyModeling andMolecular Docking on Muscarinic M₁ Receptor [J]. Acta Phys. -Chim. Sin., 2009, 25(07): 1259-1266.
[11]	WEI Zhuo, ZHANG Huai, CUI Wei, JI Ming-Juan. Molecular Docking and 3D-QSAR on Maleimide Derivatives as Glycogen Synthase Kinase-3β Inhibitors [J]. Acta Phys. -Chim. Sin., 2009, 25(05): 890-896.
[12]	SUN Ni-Yue, LU Tao, CHEN Ya-Dong, HAO Lan-Hu, XU Yan, LI Rui-Jun. 3D-QSAR and Molecular Docking Study on Selectivity of Indolocarbazole Series as Cyclin-Dependent Kinase Inhibitors [J]. Acta Phys. -Chim. Sin., 2009, 25(04): 645-654.
[13]	ZHAO Yong-Shan, ZHENG Qing-Chuan, ZHANG Hong-Xing, CHU Hui-Ying, SUN Chia-Chung. Homology Modeling of Human Serine Racemase and Its Molecular Docking with Peptide Inhibitors [J]. Acta Phys. -Chim. Sin., 2009, 25(03): 417-422.
[14]	YAN Lin-Fang, HU Gui-Xiang, XU Jing, ZHAO Wen-Na, YU Qing-Sen. 3D-QSAR Models on Cholesteryl Ester Transfer Protein Inhibitors [J]. Acta Phys. -Chim. Sin., 2008, 24(12): 2249-2256.
[15]	JIANG Yu-Ren; QIN Wei. 3D-QSAR Analysis on Benzoxazinone Derivatives [J]. Acta Phys. -Chim. Sin., 2008, 24(10): 1859-1863.

Homology Modeling, Molecular Docking, and 3D-QSAR of Indirubin Analogues as CDK1 Inhibitors

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 0